Key result
Lung cancer is associated with earlier VTE onset versus other solid tumors, occurring at median 4 months.
Why the study?
Lung cancer is the most frequent solid tumor and common in cancer-related venous thromboembolism, but clinical characteristics and outcomes compared to other cancers were unclear.
Does lung cancer compared to other solid tumors affect the timing, presentation, and clinical outcomes of venous thromboembolism in cancer patients?
Observational (n=340)
No
Does lung cancer compared to other solid tumors affect the timing, presentation, and clinical outcomes of venous thromboembolism in cancer patients?
Absolute Event Rate: 4% vs 7%
p-value: p=<0.0001
Patients with lung cancer develop venous thromboembolism earlier and present more frequently with pulmonary embolism compared to those with other solid tumors, though long-term VTE-related outcomes are similar.
Lung cancer may warrant earlier VTE vigilance than other tumors; this cohort study leaves open whether timing differences should alter prophylaxis guidelines.
Background: Lung cancer (LC) is the most frequent solid tumor diagnosed worldwide and is one of the most common tumors in series of patients with cancer-related venous thromboembolism (VTE).The aim of this study was to analyze the clinical characteristics and outcome of VTE in patients with LC compared to patients with other types of cancer (OC). Patients and Methods:A prospective observational study enrolling consecutive cancer patients with newly diagnosed VTE was performed from May 2006 to April 2009 in our Department of Medical Oncology.All patients were uniformly treated and followed according to the American College of Chest Physicians guidelines. Advances in Cancer: Research & Treatment 2Results: A total of 340 cancer patients were enrolled with LC being the most frequent primary tumor in 89 (26%) patients (69 male; mean age 62 ± 11 years).VTE was diagnosed earlier in patients with LC after the initial cancer diagnosis, with a median of 4 months (95% CI 2.79-5.20)compared to 7 months (95% CI 4.40-9.59) in patients with OC (p<0.0001).The VTE presented as pulmonary embolism in a higher proportion of patients with LC (51% vs 28%, p=0.005) although there were no differences in VTE-related outcomes due to the acute thrombotic event.After a mean follow-up of 14 ± 13 months no significant differences were found in venous re-thrombosis, major-bleeding or causes of death in patients with LC and OC.Conclusion: VTE in patients with LC occurs earlier after cancer diagnosis although no differences in VTE-related outcomes were observed compared to patients with OC.
No takes yet. Share an insight, caveat, or question.
Font et al. (2013) conducted an observational in Venous thromboembolism in cancer patients (n=340). Lung cancer vs. Other solid tumors was evaluated on Median time to VTE index event after cancer diagnosis (months) (p=<0.0001). Lung cancer patients developed venous thromboembolism significantly earlier after their initial cancer diagnosis compared to patients with other solid tumors (median 4 vs 7 months).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: